Semaglutide 3 mg

DRUG2 trials

Sponsors

Novo Nordisk A/S, University College, London

Conditions

DiabetesDiabetes Mellitus, Type 2Metabolic SyndromeObesity

Phase 1

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

CompletedNCT03638778

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-08-17End: 2018-12-05Updated: 2019-11-14

Phase 3

Semaglutide 2.4 mg in Patients With Poor Weight-loss

Active, not recruitingNCT05073835

University College, LondonDiabetes, Metabolic Syndrome, Obesity

Start: 2022-11-01End: 2025-09-30Updated: 2024-12-06